Achieve life sciences announces initiation of the phase 3 orca-3 clinical trial evaluating cytisinicline for smoking cessation

Seattle and vancouver, british columbia, jan. 25, 2022 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of orca-3, the confirmatory phase 3 trial required for registrational approval of cytisinicline in the united states. orca-3 will evaluate the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites.
ACHV Ratings Summary
ACHV Quant Ranking